{"id":4390,"date":"2018-06-10T05:50:55","date_gmt":"2018-06-10T09:50:55","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=4390"},"modified":"2018-06-10T05:50:55","modified_gmt":"2018-06-10T09:50:55","slug":"ipo-pipeline-update-ending-6-08-18","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/ipo-pipeline-update-ending-6-08-18\/","title":{"rendered":"IPO Pipeline Update – Ending 6.08.18"},"content":{"rendered":"

IPO Boutique keeps apprised of the active pipeline. Currently there are 76 active IPOs in the pipeline as of June 8, 2018. No SPACs or Unit Offerings are included. While the numbers may look diminished, we outlined why \u201clooks may be perceiving\u201d when it comes to the IPO pipeline\u00a0in this article.<\/strong><\/a><\/p>\n

\"Screen<\/a><\/p>\n

NEW FILINGS<\/strong><\/span><\/p>\n

Company: Forty Seven, Inc.
\nSymbol: FTSV
\nDescription: They are a clinical-stage immuno-oncology company focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Morgan Stanley, Credit Suisse
\nCo-Manager(s): BTIG, Canaccord Genuity, Oppenheimer & Co.
\nFiled: 6-1-18<\/p>\n

Company: AFG Holdings, Inc.
\nSymbol: AFGL
\nDescription: They are a leading original equipment manufacturer that designs and manufactures highly-engineered, mission critical equipment and provides complementary consumable products, parts and aftermarket services
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Goldman Sachs, Credit Suisse, Simmons & Company International, Barclays, Citigroup, Evercore ISI, Wells Fargo Securities
\nCo-Manager(s): Jefferies, Raymond James, Tudor, Pickering, Holt & Co.
\nFiled: 6-1-18<\/p>\n

Company: EverQuote, Inc
\nSymbol: EVER
\nDescription: They operate the largest online marketplace for insurance shopping in the United States.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): J.P Morgan, BofA Merrill Lynch
\nCo-Manager(s): Canaccord Genuity, JMP Securities, Needham & Company Oppenheimer & Co., Raymond James, William Blair
\nFiled: 6-1-18<\/p>\n

Company: GoodBulk Ltd.
\nSymbol: GBLK
\nDescription: They are a leading international owner and operator of dry bulk vessels, and one of the world’s largest owners of Capesize vessels. Prior to this offering, there has been no active trading market for their common shares, although the common shares are listed on the Norwegian Over-The-Counter List (the OTC), an over-the-counter market that is administered and operated by a subsidiary of the Norwegian Securities Dealers Association.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Morgan Stanley, Credit Suisse
\nCo-Manager(s): Clarksons Platou Securities Evercore ISI, Pareto Securities, UBS Investment Bank, ABN AMRO
\nFiled: 6-1-18<\/p>\n

Company: Translate Bio, Inc.
\nSymbol: TBIO
\nDescription: They are a leading messenger RNA, or mRNA, therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Citigroup, Leerink Partners, Evercore ISI
\nFiled: 6-1-18<\/p>\n

Company: Domo, Inc.
\nSymbol: DOMO
\nDescription: Domo is an operating system that powers a business, enabling all employees to access real-time data and insights and take action from their smartphone.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Morgan Stanley, Allen & Company, Credit Suisse, UBS Investment Bank
\nCo-Manager(s): William Blair, JMP Securities, Cowen
\nFiled: 6-1-18<\/p>\n

Company: Tricida, Inc.
\nSymbol: TCDA
\nDescription: Their goal is to slow the progression of chronic kidney disease, or CKD, through the treatment of metabolic acidosis.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Goldman Sachs, J.P. Morgan, Cowen
\nFiled: 6-4-18
\nListed Cash Raise: $150m<\/p>\n

Company: Cornerstone Management, Inc.
\nSymbol: CSCA
\nDescription: They are a private equity fund manager in China primarily engaged in the management of private equity funds.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Viewtrade Securities
\nFiled: 6-5-18
\nListed Cash Raise: $70m<\/p>\n

TERMS ADDED<\/strong><\/span><\/p>\n

Company: Puxin Limited
\nSymbol: NEW
\nDescription: They are a successful consolidator of the after-school education industry in China.
\nTrade Date: 6\/15
\nShares: 7.2 million
\nPrice Range: $17.00-$20.00
\nUnderwriter(s): Citigroup, Deutsche Bank, Barclays, Haitong International, CICC
\nTerms Added: 6-1-18<\/p>\n

Company: Adaptive Insights, Inc.
\nSymbol: ADIN
\nDescription:
\nTrade Date: 6\/14
\nShares: 8.2 million
\nPrice Range: $13.00-$15.00
\nUnderwriter(s): Morgan Stanley, BofA Merrill Lynch, Jefferies, RBC Capital
\nCo-Manager(s): JMP Securities, Oppenheimer & Co.
\nTerms Added: 6-4-18<\/p>\n

Company: Charah Solutions, Inc.
\nSymbol: CHRA
\nDescription: They are a leading provider of mission-critical environmental and maintenance services to the power generation industry.
\nTrade Date: 6\/14
\nShares: 7.4 million
\nPrice Range: $16.00-$18.00
\nUnderwriter(s): Morgan Stanley, BofA Merrill Lynch, Stifel
\nCo-Manager(s): Macquarie Capital, First Analysis Securities, Houlihan Lokey
\nTerms Added: 6-4-18<\/p>\n

Company: U.S. Xpress Enterprises, Inc.
\nSymbol: USX
\nDescription: They are the fifth largest asset-based truckload carrier in the United States by revenue, generating over $1.5 billion in total operating revenue in 2017.
\nTrade Date: 6\/14
\nShares: 18.05 million
\nPrice Range: $18.00-$20.00
\nUnderwriter(s): BofA Merrill Lynch, Morgan Stanley, J.P. Morgan, Wells Fargo Securities
\nCo-Manager(s): Stephens Inc., Stifel, Wolfe Capital Markets
\nTerms Added: 6-4-18<\/p>\n

Company: Avalara, Inc.
\nSymbol: AVLR
\nDescription: They provide a leading suite of cloud-based solutions designed to improve accuracy and efficiency by automating the processes of determining taxability, identifying applicable tax rates, determining and collecting taxes, preparing and filing returns, remitting taxes, maintaining tax records, and managing compliance documents.
\nTrade Date: 6\/15
\nShares: 7.5 million
\nPrice Range: $19.00-$21.00
\nUnderwriter(s): Goldman Sachs & Co., J.P. Morgan, BofA Merrill Lynch
\nCo-Manager(s): JMP Securities, KeyBanc Capital, Stifel
\nTerms Added: 6-4-18<\/p>\n

Company: Verrica Pharmaceuticals Inc.
\nSymbol: VRCA
\nDescription: They are a clinical-stage medical dermatology company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs.
\nTrade Date: 6\/15
\nShares: 5 million
\nPrice Range: $14.00-$16.00
\nUnderwriter(s): BofA Merrill Lynch, Jefferies, Cowen
\nTerms Added: 6-5-18<\/p>\n

Company: Electrocore, LLC
\nSymbol: ECOR
\nDescription: They are a commercial-stage bioelectronic medicine company with a platform non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology.
\nTrade Date: 6\/22
\nShares: 4.33 million
\nPrice Range: $14.00-$16.00
\nUnderwriter(s): Evercore ISI, JMP Securities, BTIG
\nTerms Added: 6-5-18<\/p>\n

Company: Eidos Therapeutics, Inc.
\nSymbol: EIDX
\nDescription: They are a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR.
\nTrade Date: 6\/20
\nShares: 6.25 million
\nPrice Range: $15.00-$17.00
\nUnderwriter(s): J.P. Morgan, BofA Merrill Lynch
\nCo-Manager(s): Barclays
\nTerms Added: 6-8-18<\/p>\n

Company: Magenta Therapeutics, Inc.
\nSymbol: MGTA
\nDescription: They are a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients.
\nTrade Date: 6\/21
\nShares: 6.67 million
\nPrice Range: $14.00-$16.00
\nUnderwriter(s): J.P. Morgan, Goldman Sachs, Cowen
\nCo-Manager(s): Wedbush PacGrow
\nTerms Added: 6-8-18<\/p>\n

Company: Kezar Life Sciences, Inc.
\nSymbol: KZR
\nDescription: They are a clinical-stage biotechnology company, discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer.
\nTrade Date: 6\/21
\nShares: 4.67 million
\nPrice Range: $14.00-$16.00
\nUnderwriter(s): Jefferies, Cowen, Wells Fargo, William Blair
\nTerms Added: 6-8-18<\/p>\n

Company: Autolus Therapeutics Limited
\nSymbol: AUTL
\nDescription: They are a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer.
\nTrade Date: 6\/22
\nShares: 7.81 million
\nPrice Range: $15.00-$17.00
\nUnderwriter(s): Goldman Sachs & Co., Jefferies
\nCo-Manager(s): Wells Fargo Securities, William Blair
\nTerms Added: 6-8-18<\/p>\n","protected":false},"excerpt":{"rendered":"

IPO Boutique keeps apprised of the active pipeline. Currently there are 76 active IPOs in the pipeline as of June 8, 2018. No SPACs or Unit Offerings are included. While the numbers may look diminished, we outlined why \u201clooks may be perceiving\u201d when it comes to the IPO pipeline\u00a0in this article. NEW FILINGS Company: Forty[…]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[1],"tags":[],"class_list":["post-4390","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=4390"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4390\/revisions"}],"predecessor-version":[{"id":4392,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4390\/revisions\/4392"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=4390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=4390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=4390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}